State Street® SPDR® S&P® PhrmctlsETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
State Street® SPDR® S&P® Pharmaceuticals ETF XPH
Morningstar’s Analysis XPH
Will XPH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 24.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.76 | 17M | Healthcare |
MBX Biosciences Inc | 2.98 | 14M | Healthcare |
AtaiBeckley Inc | 2.92 | 14M | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 2.83 | 13M | Healthcare |
Enliven Therapeutics Inc | 2.15 | 10M | Healthcare |
Alumis Inc | 2.14 | 10M | Healthcare |
Nuvation Bio Inc Ordinary Shares - Class A | 2.10 | 10M | Healthcare |
Amylyx Pharmaceuticals Inc | 1.99 | 9M | Healthcare |
Trevi Therapeutics Inc | 1.92 | 9M | Healthcare |
Harrow Inc | 1.90 | 9M | Healthcare |